Extraordinary Index Rebalancing in the Solactive China Healthcare Disruption Index | November 2021
Due to the IPO of SHANGHAI MICROPORT MEDBOT GR, the company will be added via an extraordinary rebalance effective open 22.11.2021.
In the extraordinary rebalance the following composition will be implemented effective open 22.11.2021:
ALIBABA HEALTH INFORMATION TECHNOLOGY LTD |
MICROPORT SCIENTIFIC CORP |
CHINA MEDICAL SYSTEM HOLDINGS LTD |
SHANDONG WEIGAO GROUP MEDICAL POLYMER CO LTD |
SINO BIOPHARMACEUTICAL LTD ORD |
LIFETECH SCIENTIFIC CORP |
3SBIO INC |
GENSCRIPT BIOTECH CORP |
INNOVENT BIOLOGICS INC |
PING AN HEALTHCARE AND TECHNOL |
SHANGHAI JUNSHI BIOSCIENCES CO LTD |
EVEREST MEDICINES LTD |
SIMCERE PHARMACEUTICAL GROUP |
BRII BIOSCIENCES LTD |
YIDU TECH INC |
MICROPORT CARDIOFLOW MEDTECH |
CARSGEN THERAPEUTICS HOLDING |
SHANGHAI MICROPORT MEDBOT GR |
WUXI BIOLOGICS CAYMAN INC |
WUXI APPTEC CO LTD |
VENUS MEDTECH HANGZHOU INC |
HANSOH PHARMACEUTICAL GROUP CO |
JOINN LABORATORIES CHINA C-H |
BEIGENE LTD |
CANSINO BIOLOGICS INC |
NEW HORIZON HEALTH LTD |
JD HEALTH INTERNATIONAL INC |
ANGELALIGN TECHNOLOGY INC |
ZAI LAB LTD |
AKESO INC |
KINTOR PHARMACEUTICAL LTD |
ALPHAMAB ONCOLOGY |
INNOCARE PHARMA LTD |
REMEGEN CO LTD-H |
PEIJIA MEDICAL LTD |